8-K Announcements
6Material company update
Mar 11, 2026·SEC
Material company update
Feb 9, 2026·SEC
Material company update
Dec 12, 2025·SEC
Anixa Biosciences, Inc.(ANIX)Earnings, Financials & Key Ratios
ANIX•NASDAQ
$2.79
Price updated Jun 27, 2026
AboutAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Show more
- Revenue$0
- EBITDA-$12M+15.4%
- Net Income-$11M+13.0%
- EPS (Diluted)-0.34+12.8%
- ROE-66.55%-12.0%
ANIX Price & Volume
Anixa Biosciences, Inc. (ANIX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Anixa Liquidity Position
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Anixa Biosciences remains in a high-risk, pre-revenue stage, with its valuation heavily dependent on the clinical success of its oncology and vaccine pipeline. The company's reliance on external partners and consistent quarterly operating losses of approximately $3 million necessitate frequent capital infusions, which may lead to significant shareholder dilution. Investors should monitor the company's ability to extend its limited cash runway, as the current asset-light model provides little buffer against potential clinical trial delays."
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $1.5 million against a quarterly burn rate of $1.7 million, suggests an imminent and highly dilutive capital raise is required to maintain operations.
ANIX Growth Metrics
Anixa Biosciences, Inc. (ANIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2157.24%
Return on Capital
10 Years-103.98%
5 Years-56.49%
3 Years-59.3%
Last Year-70.48%
ANIX Recent Earnings
Anixa Biosciences, Inc. (ANIX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q3 2026Latest
Jun 10, 2026Metric
Actual
Est
EPS
$0.07+30.0%
$0.10
Rev
—
—
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.08+11.1%
$0.09
Rev
—
—
Q1 2026
Jan 12, 2026Metric
Actual
Est
EPS
$0.09-2.3%
$0.09
Rev
—
—
Q4 2025
Sep 10, 2025Metric
Actual
Est
EPS
$0.07+30.0%
$0.10
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 10, 2026 | $0.07vs $0.10+30.0% | — |
| Q2 2026 | Mar 9, 2026 | $0.08vs $0.09+11.1% | — |
| Q1 2026 | Jan 12, 2026 | $0.09vs $0.09-2.3% | — |
| Q4 2025 | Sep 10, 2025 | $0.07vs $0.10+30.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Anixa Biosciences, Inc. (ANIX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.79 | $94.92M | -8.21 | — | — | -66.55% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — |
Compare ANIX vs Peers
Anixa Biosciences, Inc. (ANIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANIX SEC Filings & Documents
Anixa Biosciences, Inc. (ANIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ANIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANIX Frequently Asked Questions
Anixa Biosciences, Inc. (ANIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ANIX profitable?
Anixa Biosciences, Inc. (ANIX) reported a net loss of $10.1M for fiscal year 2025.
Dividend & Returns
What is ANIX's return on equity?
Anixa Biosciences, Inc. (ANIX) has a return on equity (ROE) of -66.6%. Negative ROE indicates the company is unprofitable.
What is Anixa Biosciences, Inc.'s free cash flow?
Anixa Biosciences, Inc. (ANIX) had negative free cash flow of $7.1M in fiscal year 2025, likely due to heavy capital investments.